Details of Disease

General Information of Disease (ID: DISHJTI4)

• Disease Name: Influenza A virus H1N1 infection
• Disease Class: 1E30-1E32: Influenza
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISHJTI4: Influenza A virus H1N1 infection
• ICD Code:
  ICD-11: ICD-11: 1E30
  Expand ICD-9: 487488

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK-692342	DM7ON1I	Phase 2	NA	[1]
GSK2340273A	DMDLF6K	Phase 2	NA	[2]
SAB-176	DMMADH4	Phase 2	NA	[3]
FVh1 DNA-based influenza vaccine	DMRQ4DI	Phase 1	NA	[4]
Ii-Key hybrid peptide vaccine	DMVGJ84	Phase 1	NA	[5]
Influenza A virus vaccine H1N1	DMKJ3EM	Phase 1	NA	[6]
Influenza virus DNA vaccine	DMIHII8	Phase 1	NA	[7]
VAX-128	DM2LRDS	Phase 1	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024374)
• [2] ClinicalTrials.gov (NCT00976820) Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04850898) Study of SAB-176 in Healthy Adult Participants. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01587131) DNA-based Influenza Vaccine in the Elderly. U.S. National Institutes of Health.
• [5] Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res. 2010 Jul 1;16(13):3495-506.
• [6] Clinical pipeline report, company report or official report of Medicago Inc.
• [7] Clinical pipeline report, company report or official report of Vical.
• [8] ClinicalTrials.gov (NCT01172054) Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults. U.S. National Institutes of Health.